Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1521-1530 of 1,873) with videos related to

Pageof 188
Sort By:
Biorxiv : the Preprint Server for Biology|June 5, 2026
PIEZO1-mediated mechanosensation links aging to bladder dysfunctionYasmeen M F Hamed, Vikram Joshi, Kevin Wilhelm, et al.
Journal of Medical Genetics|April 19, 2014
Pathogenic mutations in GLI2 cause a specific phenotype that is distinct from holoprosencephalyKelly A Bear, Benjamin D Solomon, Sonir Antonini, et al.
Human Vaccines & Immunotherapeutics|January 8, 2026
A Bayesian re-analysis of the DANFLU-1 trialDaniel Modin, Niklas Dyrby Johansen, Anders Granholm, et al.
European Journal of Heart Failure|July 17, 2024
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVERAmr Abdin, Toru Kondo, Michael Böhm, et al.
Circulation. Cardiovascular Quality and Outcomes|August 31, 2024
Relative Effectiveness of High-Dose Versus Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical TrialJacob Christensen, Niklas Dyrby Johansen, Daniel Modin, et al.
European Journal of Heart Failure|April 11, 2025
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
ESC Heart Failure|June 23, 2022
Pharmacogenomic study of heart failure and candesartan response from the CHARM programmeMarie-Pierre Dubé, Olympe Chazara, Audrey Lemaçon, et al.
JAMA|May 12, 2024
Cardiovascular Burden of the V142I Transthyretin VariantSenthil Selvaraj, Brian Claggett, Svati H Shah, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
Pageof 188

Showing results (1521-1530 of 1,873) with videos related to

Sort By:
Pageof 188
Biorxiv : the Preprint Server for Biology|June 5, 2026
PIEZO1-mediated mechanosensation links aging to bladder dysfunctionYasmeen M F Hamed, Vikram Joshi, Kevin Wilhelm, et al.
Journal of Medical Genetics|April 19, 2014
Pathogenic mutations in GLI2 cause a specific phenotype that is distinct from holoprosencephalyKelly A Bear, Benjamin D Solomon, Sonir Antonini, et al.
Human Vaccines & Immunotherapeutics|January 8, 2026
A Bayesian re-analysis of the DANFLU-1 trialDaniel Modin, Niklas Dyrby Johansen, Anders Granholm, et al.
European Journal of Heart Failure|July 17, 2024
Effects of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction: An analysis of DAPA-HF and DELIVERAmr Abdin, Toru Kondo, Michael Böhm, et al.
Circulation. Cardiovascular Quality and Outcomes|August 31, 2024
Relative Effectiveness of High-Dose Versus Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical TrialJacob Christensen, Niklas Dyrby Johansen, Daniel Modin, et al.
European Journal of Heart Failure|April 11, 2025
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.
ESC Heart Failure|June 23, 2022
Pharmacogenomic study of heart failure and candesartan response from the CHARM programmeMarie-Pierre Dubé, Olympe Chazara, Audrey Lemaçon, et al.
JAMA|May 12, 2024
Cardiovascular Burden of the V142I Transthyretin VariantSenthil Selvaraj, Brian Claggett, Svati H Shah, et al.
Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.
Circulation. Heart Failure|August 15, 2014
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) TrialAmil M Shah, Brian Claggett, Nancy K Sweitzer, et al.
Pageof 188